Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
about
Cytotoxic and targeted therapy for hereditary cancersAmerican Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care GuidelineNovel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibitionPeptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domainPredictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repairHistone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsYAP regulates S-phase entry in endothelial cellsHP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients'BRCAness' and its implications for platinum action in gynecologic cancer.Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair.Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.TGFbeta and miRNA regulation in familial and sporadic breast cancer.BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication forkEfficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.
P2860
Q26739366-44D45EA7-564F-42BD-B435-F5B8654B67DDQ26773986-49C1005D-BF65-479C-B34A-94908849D7F4Q26851765-AE3E10DD-02E7-4AD9-A430-AC65240497BDQ28256541-085BA493-D920-45DC-973B-5935DB90731EQ33441772-CB7EF0DB-4F1D-46EC-AF71-4FDE97FC3D31Q33635645-953666F6-E404-4914-8639-E5142AD89C81Q34221822-2417115A-BA95-4E2E-A4B7-5B8A56058A01Q35031979-76CE6DD1-6C8B-407F-A100-7D1F67EDA1F0Q35175294-9854F1A9-C537-4B02-B108-C46F9F110D4DQ36039509-7E49C62C-84B1-44F3-A15F-4654D5FC8358Q36380704-9168BE56-1BBA-4364-9960-B66CEA23D07CQ37046504-2C1C1F65-E463-4964-B160-2C3F5F148E62Q37385372-C5576C41-4FD3-4D39-B385-9915EBBE06C6Q37734389-EB3A79D7-1C68-4796-B1FF-052A3EFF8EF9Q38938253-971D2F03-CDA6-4198-B209-C8E29A896102Q39428059-C79BC382-FCD4-41EE-B49D-051EDCAF75EFQ41612388-3EB5F304-D529-42DA-92F2-7378BB7B2C44Q42062001-0597B943-9AFC-4B7F-83F1-40C00236F0E1Q47939487-C6520388-90DC-41A0-ADB4-2910184365ADQ48163701-42F6D461-8829-4EDF-8759-898CDBCF0B40Q48596039-A777CC2B-7B16-41F1-9C33-E952494FD240Q49909339-AB35DDE4-B87C-4C5E-97DD-289B48D3282A
P2860
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
@en
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
@nl
type
label
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
@en
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
@nl
prefLabel
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
@en
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
@nl
P2860
P1433
P1476
Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
@en
P2093
Pavani Chalasani
Robert Livingston
P2860
P304
P356
10.1634/THEONCOLOGIST.2013-0039
P577
2013-07-23T00:00:00Z